Alnylam Pharmaceuticals
ALNY
#572
Rank
C$51.69 B
Marketcap
$400.82
Share price
1.16%
Change (1 day)
66.05%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.94. In 2022 the company made an earnings per share (EPS) of -$13.43 a decrease over its 2021 EPS that were of -$10.41.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-59.08%
2022-$13.4329.03%
2021-$10.41-3.36%
2020-$10.77-8.48%
2019-$11.777.67%
2018-$10.9339.74%
2017-$7.8212.94%
2016-$6.9338.84%
2015-$4.99-32.88%
2014-$7.43259.44%
2013-$2.07-31.25%
2012-$3.0152.94%
2011-$1.9730.77%
2010-$1.50-8.77%
2009-$1.6578.13%
2008-$0.93-70.78%
2007-$3.1799.09%
2006-$1.59-43.88%
2005-$2.83-82.33%
2004-$16.04-59.23%
2003-$39.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.46-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$54.03-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.32 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.39-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.44-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.41-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.60-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.89-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel